(R)-5-(2-aminopropyl)-1-(3-benzyloxypropyl) indoline-7-carbonitrile

We are (R)-5-(2-aminopropyl)-1-(3-benzyloxypropyl) indoline-7-carbonitrile CAS:459868-73-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(R)-5-(2-aminopropyl)-1-(3-benzyloxypropyl) indoline-7-carbonitrile
CAS.NO:459868-73-6
Synonyms:(R)-5-(2-aminopropyl)-1-(3-benzyloxypropyl) indoline-7-carbonitrile
5-[(2R)-2-aminopropyl]-1-(3-phenylmethoxypropyl)-2,3-dihydroindole-7-carbonitrile
5-[(2R)-2-Aminopropyl]-2,3-dihydro-1-[3-(phenylmethoxy)propyl]-1H-indole-7-carbonitrile
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 539.3±50.0 °C at 760 mmHg
Molecular Formula C22H27N3O
Molecular Weight 349.469
Flash Point 280.0±30.1 °C
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Silodosin(CAS:160970-54-7).

(R)-5-(2-aminopropyl)-1-(3-benzyloxypropyl) indoline-7-carbonitrile


Related News: As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company’s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations.2-Bromoethyl acetate These include: high-barrier generic drug substances and commonly used generic drug substances.50-85-1 Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.4-bromo-2-metilpiridina CAS:22282-99-1 Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.This includes chemical APIs.

Related Products
Product Name
3-Bromo-6-hydroxy-2-methylpyridine View Details
2,2-Diethoxytriethylamine View Details
2-methoxy-3-nitropyridine View Details
Bromoacetyl chloride manufacturer N-Boc-piperazine manufacturer 2-methylfuran-3-thiol manufacturer 1-methylsulfanylpropan-2-one manufacturer Morpholinosulfur trifluoride manufacturer